Kancera AB operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kancera AB with three other
pharmaceutical manufacturers in Europe:
sales of 252,773.00 Euros [US$294,606.93 ]
of which 100%
was The conduct of research and development ),
Oasmia Pharmaceutical AB
(1.98 million Swedish Kronor [US$219,502.80 ]
of which 65%
was Sales of goods), and
based in UNITED KINGDOM
(£322,189.00 [US$409,908.18 ]
Sales increased substantially in 2019:
Kancera AB reported sales of SEK 3.22 million (US$356.53 thousand)
December of 2019.
increase of 798.3%
versus 2018, when the company's sales were SEK 358,000.00 .